ロード中...
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations
Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia (CML). Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2000-fold lower. Imatinib recognition...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2678021/ https://ncbi.nlm.nih.gov/pubmed/19276351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3953 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|